Gentronix Ltd, a UK-based contract research firm, received £750k in third funding.
The Northern Venture Capital Trust Funds (VCTs), which are managed by Mercia, made the investment.
The company intends to use the funds to create 30 new jobs and to expand its capabilities and services.
Led by Matt Tate, CEO, Gentronix provides toxicology testing services for pharmaceuticals, agrochemicals, cosmetics, personal care and consumer products. The company enables major global brands to perform hazard and safety assessments, from early stage discovery through to regulatory submission and approval. Services are delivered by an expert scientific team, with a focus on minimal use of test substances and responsive timeframes.